Acetaminophen Could Have Exemption ‘Qualifications’ If Added To Prop 65
Executive Summary
If acetaminophen is added to California's Prop 65 list, it would likely be a qualified listing, requiring OTC marketers only warn consumers under special circumstances, says a consumer products lawyer. Listing could spur argument between stakeholders and the state over FDA labeling pre-emption.
You may also be interested in...
FDA Preemption Comment Could Sway California Against Prop 65 Warnings For Acetaminophen
Food and drug attorneys suggest it is unlikely California will require Prop 65 warnings on OTC acetaminophen products after FDA tells the state that warnings would violate federal regulations. FDA also says sciences doesn't support a conclusion acetaminophen can cause cancer and that the warnings would confuse consumers.
US Health Market In 2019: Unfinished Business Leaves Lasting Impression
Examples of unfinished business from 2019 include no legislation passed to reform OTC monograph program; FDA putting off until May the planned publication of an NPRM to allow firms to submit OTC NDAs with extra-label information to help guide consumers' self-selection; and no OTC naloxone for opioid overdose approved even after FDA's unprecedented step of developing model DFLs sponsors could use for their own label comprehension studies.
Health Market News: Acetaminophen Prop 65 Report Posted; Loperamide Brands' Smaller Packaging
Brand-name loperamide OTCs will be packaged in single doses with no more than 48 mg per container; and California posts acetaminophen hazard identification for Prop 65 consideration.